Pharmaceutical In news last week, on the clinical trials front RedHill BioPharma attracted attention with its Phase III study of Crohn’s candidate RHB-104. There was disappointment for Sienna Biopharmaceuticals as its acne vulgar drug SNA-001 failed in a Phase III study, and Epizyme’s update on tazemetostat development for lymphoma caused some concern as the company lost 24% of its market value. Regulatory news included Progenics’ rare disease drug Azedra approval by the US Food and Drug Administration also elicited comment, as did European Union approval and pending launch of Amgen and Novartis’ migraine drug Aimovig. 5 August 2018